Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Asthma
Interventions
BIOLOGICAL

Reslizumab

OTHER

Saline

Trial Locations (30)

13045

Health Sciences Research at Asthma & Allergy, Cortland

15213

University of Pittsburgh, Pittsburgh

19422

Allergy and Asthma Specialists, Blue Bell

21044

Pulmonary Disease & Critical Care Associates, P.A., Columbia

23229

Virginia Adult & Pediatric Allergy and Asthma, Richmond

23298

Virginia Commonwealth University, Richmond

27157

Wake Forest Univeristy Health Services, Winston-Salem

37203

Vanderbilt Asthma Sinus Allergy Program & Research Centers, Nashville

43560

Toledo Center for Clinical Research, Sylvania

45229

David Bernstein, Cincinnati

53228

Allergy, Asthma and Sinus Center, Greenfield

53972

University of Wisconsin-Madison, Allergy/Asthma Clinical Research Unit, Madison

55402

Clinical Research Institute, Minneapolis

61761

Sneeze, Wheeze & Itch Associates, LLC, Normal

63110

Washington University of School of Medicine, St Louis

68046

The Asthma & Allergy Center, Papillion

73120

Allergy, Asthma and Clinical Research Center, Oklahoma City

80112

Allergy & Clinical Research Center, Centennial

80206

National Jewish Medical & Research Center, Denver

80907

Asthma & Allergy Associates, P.C., Colorado Springs

92868

Children'S Hospital of Orange County-Pediatric Subspecialty Faculty, Orange

97504

Clinical Research Institute of Southern Oregon, Medford

98105

Asthma, Inc, Seatle

02115

Brigham and Women's Hospital, Boston

T2N4N1

Heritage Medical Research Clinic, University of Calgary, Calgary

L8N 4A6

St. Joseph's Healthcare, Hamilton

K7L 2V6

Queen's University, Richardson's House, Kingston

K1H 8L6

The Ottawa Hospital, Ottawa

H4J1C5

Hopital du Sacre-Couer de Montreal, Montreal

G1V4G5

Hopital Laval, Québec

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cephalon

INDUSTRY

lead

Ception Therapeutics

INDUSTRY

NCT00587288 - Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma | Biotech Hunter | Biotech Hunter